机构:[1]School of Basic Medicine, Chengdu University of Traditional Chinese Medicine Chengdu, Sichuan, PR China.[2]Department of Clinical Laboratory, The First People's Hospital of Kunming Kunming, Yunnan, PR China.
This work was
supported by the grant from the National
Natural Science Foundation of China (No.
81401904) and Science &
Technology Department of Sichuan Province, P.
R. China (No. 2018HH0005 )
语种:
外文
PubmedID:
中科院(CAS)分区:
出版当年[2018]版:
大类|4 区医学
小类|4 区肿瘤学4 区病理学
最新[2025]版:
大类|4 区医学
小类|4 区肿瘤学4 区病理学
第一作者:
第一作者机构:[1]School of Basic Medicine, Chengdu University of Traditional Chinese Medicine Chengdu, Sichuan, PR China.
通讯作者:
通讯机构:[1]School of Basic Medicine, Chengdu University of Traditional Chinese Medicine Chengdu, Sichuan, PR China.[*1]School of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, Sichuan, PR China.
推荐引用方式(GB/T 7714):
Long Ming-Peng,Wang Hui-Li,Luo Yong-Bin,et al.Targeting ROR1 inhibits epithelial to mesenchymal transition in human lung adenocarcinoma via mTOR signaling pathway.[J].International journal of clinical and experimental pathology.2018,11(10):4759-4770.
APA:
Long Ming-Peng,Wang Hui-Li,Luo Yong-Bin&Yang Jia-Hui.(2018).Targeting ROR1 inhibits epithelial to mesenchymal transition in human lung adenocarcinoma via mTOR signaling pathway..International journal of clinical and experimental pathology,11,(10)
MLA:
Long Ming-Peng,et al."Targeting ROR1 inhibits epithelial to mesenchymal transition in human lung adenocarcinoma via mTOR signaling pathway.".International journal of clinical and experimental pathology 11..10(2018):4759-4770